Regarding diseases that most affect men’s quality of life, such as cardiovascular disease (Author anonymous, 2024), which also has a higher prevalence—in global terms—in men (Ministerio de Sanidad, 2025), our study shows a series of medication groups indicated for this pathology, such as platelet aggregation inhibitors (B01AC), selective beta-blockers (C07AB), and angiotensin-converting enzyme inhibitors (C09AA), where the number of dispensations and percentages are higher in men. This evidence concerns the gene ACE and cardiovascular disorder.